drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Anti-HER2 IgG1 monoclonal antibody that blocks HER2 dimerization and mediates antibody-dependent cellular cytotoxicity (ADCC).
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
Pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 IgG1 that binds the HER2 extracellular dimerization domain, blocks HER2 dimerization and downstream signaling (e.g., PI3K/AKT/MAPK), and engages Fc-gamma receptor–bearing effector cells to mediate ADCC, leading to tumor cell growth inhibition and death.
drug_name
Pertuzumab
nct_id_drug_ref
NCT06747338